These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 7685428)

  • 1. A prospective, placebo-controlled study of the antiandrogen Casodex as treatment for patients with benign prostatic hyperplasia.
    Eri LM; Tveter KJ
    J Urol; 1993 Jul; 150(1):90-4. PubMed ID: 7685428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, side effects and patient acceptance of the antiandrogen Casodex in the treatment of benign prostatic hyperplasia.
    Eri LM; Tveter KJ
    Eur Urol; 1994; 26(3):219-26. PubMed ID: 7528662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re: A prospective, placebo-controlled study of the antiandrogen Casodex as treatment for patients with benign prostatic hyperplasia.
    Strutt KL; Blackledge GR; Kennealey GT
    J Urol; 1994 May; 151(5):1355-6. PubMed ID: 7512665
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of the nonsteroidal antiandrogen Casodex on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia.
    Eri LM; Urdal P
    Eur Urol; 1995; 27(4):274-9. PubMed ID: 7544732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerability and quality of life aspects with the anti-androgen Casodex (ICI 176,334) as monotherapy for prostate cancer. International Casodex Investigators.
    Tyrrell CJ
    Eur Urol; 1994; 26 Suppl 1():15-9. PubMed ID: 7537664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects on the endocrine system of long-term treatment with the non-steroidal anti-androgen Casodex in patients with benign prostatic hyperplasia.
    Eri LM; Haug E; Tveter KJ
    Br J Urol; 1995 Mar; 75(3):335-40. PubMed ID: 7537602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study Group.
    Tyrrell CJ; Denis L; Newling D; Soloway M; Channer K; Cockshott ID
    Eur Urol; 1998; 33(1):39-53. PubMed ID: 9471040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can prostate epithelial content predict response to hormonal treatment of patients with benign prostatic hyperplasia?
    Eri LM; Svindland A
    Urology; 2000 Aug; 56(2):261-5. PubMed ID: 10925090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Casodex (bicalutamide): overview of a new antiandrogen developed for the treatment of prostate cancer.
    Blackledge GR; Cockshott ID; Furr BJ
    Eur Urol; 1997; 31 Suppl 2():30-9. PubMed ID: 9074908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical progress with a new antiandrogen, Casodex (bicalutamide).
    Blackledge GR
    Eur Urol; 1996; 29 Suppl 2():96-104. PubMed ID: 8717470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective, placebo-controlled study of the luteinizing hormone-releasing hormone agonist leuprolide as treatment for patients with benign prostatic hyperplasia.
    Eri LM; Tveter KJ
    J Urol; 1993 Aug; 150(2 Pt 1):359-64. PubMed ID: 7686981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current clinical studies with a new nonsteroidal antiandrogen, Casodex.
    Kaisary AV
    Prostate Suppl; 1994; 5():27-33. PubMed ID: 8172713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A dose-response study of the effect of flutamide on benign prostatic hyperplasia: results of a multicenter study.
    Narayan P; Trachtenberg J; Lepor H; Debruyne FM; Tewari A; Stone N; Das S; Jimenez-Cruz JF; Shearer R; Klimberg I; Schellhammer PF; Costello AJ
    Urology; 1996 Apr; 47(4):497-504. PubMed ID: 8638357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathological and morphometric assessment of testicular parameters in patients with metastatic prostate cancer following treatment with either the antiandrogen Casodex (ZM176,334) or bilateral orchidectomy.
    Jones HB; Betton GR; Bowdler AL; McFarquhar RL; Middleton BJ; Lunglmayr G
    Urol Res; 1994; 22(3):191-5. PubMed ID: 7992465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update of monotherapy trials with the new anti-androgen, Casodex (ICI 176,334). International Casodex Investigators.
    Iversen P
    Eur Urol; 1994; 26 Suppl 1():5-9. PubMed ID: 7737258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomised comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. Casodex Study Group.
    Kaisary AV; Tyrrell CJ; Beacock C; Lunglmayr G; Debruyne F
    Eur Urol; 1995; 28(3):215-22. PubMed ID: 8536775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antagonist/agonist balance of the nonsteroidal antiandrogen bicalutamide (Casodex) in a new prostate cancer model.
    Hobisch A; Hoffmann J; Lambrinidis L; Eder IE; Bartsch G; Klocker H; Culig Z
    Urol Int; 2000; 65(2):73-9. PubMed ID: 11025427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Casodex (ICI 176,334), a new, non-steroidal anti-androgen. Early clinical results.
    Lunglmayr G
    Horm Res; 1989; 32 Suppl 1():77-81. PubMed ID: 2515147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Casodex: a pure non-steroidal anti-androgen used as monotherapy in advanced prostate cancer.
    Tyrrell CJ
    Prostate Suppl; 1992; 4():97-104. PubMed ID: 1574464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.